3-[5-(dimethylsulfamoyl)-2-methoxyphenyl]-N-[1-(5,6,7,8-tetrahydronaphthalen-2-yl)propyl]propanamide
C25H34N2O4S — CID 133191791
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[5-(dimethylsulfamoyl)-2-methoxyphenyl]-N-[1-(5,6,7,8-tetrahydronaphthalen-2-yl)propyl]propanamide
3-[5-(dimethylsulfamoyl)-2-methoxyphenyl]-N-[1-(5,6,7,8-tetrahydronaphthalen-2-yl)propyl]propanamide (PubChem CID 133191791) has the molecular formula C25H34N2O4S and a molecular weight of 458.62 g/mol. Its IUPAC name is 3-[5-(dimethylsulfamoyl)-2-methoxyphenyl]-N-[1-(5,6,7,8-tetrahydronaphthalen-2-yl)propyl]propanamide.
Molecular Properties
| Compound Name | 3-[5-(dimethylsulfamoyl)-2-methoxyphenyl]-N-[1-(5,6,7,8-tetrahydronaphthalen-2-yl)propyl]propanamide |
|---|---|
| PubChem CID | 133191791 |
| Molecular Formula | C25H34N2O4S |
| Molecular Weight | 458.62 g/mol |
| Exact Mass | 458.22 |
| IUPAC Name | 3-[5-(dimethylsulfamoyl)-2-methoxyphenyl]-N-[1-(5,6,7,8-tetrahydronaphthalen-2-yl)propyl]propanamide |
| SMILES | CCC(NC(=O)CCc1cc(S(=O)(=O)N(C)C)ccc1OC)c1ccc2c(c1)CCCC2 |
| InChI | InChI=1S/C25H34N2O4S/c1-5-23(20-11-10-18-8-6-7-9-19(18)16-20)26-25(28)15-12-21-17-22(13-14-24(21)31-4)32(29,30)27(2)3/h10-11,13-14,16-17,23H,5-9,12,15H2,1-4H3,(H,26,28) |
| InChIKey | KJNLIGZXGHGSIY-UHFFFAOYSA-N |
| XLogP | 4.02 |
| TPSA | 75.71 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 458.62 |
| LogP ≤ 5 | 4.02 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 133191791 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.